Indianapolis-based MHP Pharmacy’s facility on North Meridian Street will close in August as a result of the company’s purchase
by In Touch Pharmaceuticals in Valparaiso.
Eli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine’s use to patients whose
disease is in an earlier stage.
The Indianapolis-based insurer’s first-quarter spending is 16 percent more than it spent in the same quarter last year and
in the fourth quarter of 2009.
Having invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
Not-for-profit launched last year by BioCrossroads and Indiana’s orthopedic companies names Zimmer Inc. executive Brad Bishop
to lead the initiative.
Locally based SynCare LLC has withdrawn a request for a property tax abatement tied to the creation of 114 jobs. SynCare owner
Stephanie DeKemper said she pulled the request to ensure the employment projections are accurate.
SynCare LLC’s expansion hinges on city approval of property tax abatement. The Metropolitan Development Commission is set
to vote on the request Wednesday.
A deal in which St. Vincent Health would buy or lease Bedford’s Dunn Memorial Hospital is in the final stages, according
to the Times-Mail of Bedford. The hospital board held two hours of closed-door talks on May 26, and one board member
predicted a decision within days.
The much-maligned health care bill provides a huge opportunity for local communities to improve the health of their citizens
and for local health care providers to win bonus payments from federal health insurance programs. That's the message Len
Nichols, a Beltway veteran and health policy expert, will bring to attendees at the All Healthcare is Local conference today.
The drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
In 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
In the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
In the company's latest response to withering criticism of its breast-cancer policies, WellPoint Inc. said it will pay
for any breast cancer patient to stay two days in a hospital after surgery.
Now that health reform is law, a local not-for-profit group, Better Healthcare for Indiana, wants to help Indiana community
leaders use the law to slow runaway medical spending while improving the health of their citizens.
WellPoint Inc.'s announcement of comparative effectiveness research guidelines last week marks a new era for U.S. drugmakers.
The Indianapolis-based health insurer will use studies that compare the effectiveness of one drug against another as a complement
to typical clinical trial research that compares a drug against a placebo sugar pill.
Don Stumpp, manager of payer contracting at Indianapolis-based physician group American Health Network and president of the Indiana Medical Group Management Association, discussed the impact of the health care reform law on primary care physicians as well as the near-constant threat of a sharp cut in Medicare reimbursement.
Indianapolis-based Eli Lilly and Co. spent about $2.3 million in the first quarter of 2010 lobbying the federal government
on health care reform, Medicare reimbursement and trade issues among other topics.
